JNJ Offers Better Value Than KO After Q1 2026 Beats
Johnson & Johnson's cheaper valuation and robust oncology pipeline make it a more compelling defensive play than Coca-Cola following both companies' first-quarter earnings beats.
Capital rotating out of technology has pushed both Johnson & Johnson and Coca-Cola to recent highs, but their first-quarter 2026 results reveal diverging fundamentals beneath the surface. JNJ shares broke past $259, while KO tagged an all-time high near $84.14. For investors seeking defensive anchors, the valuation gap between the two has become hard to ignore.
JNJ generated $24.062 billion in revenue, up 9.9% year over year, with adjusted earnings per share of $2.70. The results were driven by a successful transition away from legacy blockbusters facing biosimilar competition. DARZALEX revenue surged 22.5% to $3.964 billion, and TREMFYA soared 68.3% to $1.608 billion, offsetting a 59.7% plunge in STELARA sales. CEO Joaquin Duato called it "a strong start to 2026" and raised full-year revenue guidance to $100.3 billion to $101.3 billion.
The pharmaceutical giant's bottom line remains clouded by one-time charges, with net income falling 52.4% due to $330 million in litigation costs and free cash flow declining. However, the market is looking past the noise. Polymarket traders imply a 92% probability that JNJ will beat its next earnings estimate, bolstered by 28 separate billion-dollar product platforms and a planned Orthopaedics spinoff.
Coca-Cola posted a cleaner headline number, with revenue rising 12.1% to $12.472 billion and EPS of $0.86 beating estimates by 5.87%. CEO Henrique Braun attributed the performance to "staying close to the consumer, executing locally and managing complexity." The company expanded its operating margin to 35.0% from 32.9%, driven partly by a 13% jump in Zero Sugar volumes across all regions.
Despite the margin expansion, Coca-Cola's underlying volume grew just 3%, meaning the bulk of its 10% organic revenue growth came from price increases. This pricing-driven model carries reversal risk in a slowing economy. Trading at a 26x forward price-to-earnings multiple compared to JNJ's 23x, Coca-Cola leaves little room for error. For market professionals pricing in risk, JNJ's double-digit oncology growth provides a stronger margin of safety at a lower valuation.
